Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low-dose thalidomide in myelofibrosis.

Literature DB >> 18508796

Low-dose thalidomide in myelofibrosis.

Robert Weinkove, John T Reilly, Mary Frances McMullin, Natasha J Curtin, Deepti Radia, Claire N Harrison.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2008 PMID： 18508796 DOI： 10.3324/haematol.12416

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

Review 1. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors: Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal: Curr Hematol Malig Rep Date: 2019-08 Impact factor: 3.952

Review 2. Management of Myelofibrosis-Related Cytopenias.

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Curr Hematol Malig Rep Date: 2018-06 Impact factor: 3.952

Review 3. SOHO State-of-the-Art Update and Next Questions: MPN.

Authors: Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal: Clin Lymphoma Myeloma Leuk Date: 2018-01

4. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544

5. Human Immunodeficiency Virus Related Myelofibrosis Responsive to Low Dose Thalidomide.

Authors: Sunita Sharma; Jagdish Chandra; Rohini Gupta; Richa Chauhan
Journal: Indian J Pediatr Date: 2016-05-11 Impact factor: 1.967

6. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors: Prithviraj Bose
Journal: Expert Opin Orphan Drugs Date: 2019-09-24 Impact factor: 0.694

Review 7. JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Authors: Andrew T Kuykendall; Rami S Komrokji
Journal: J Immunother Precis Oncol Date: 2021-06-22